One Drop touted data today from a retrospective study of people with Type I and Type II diabetes using its mobile diabetes management app. The data, which were published yesterday in JMIR Diabetes, showed that people using the One Drop mobile app had a 1.1% to 1.3% absolute reduction in A1C in 4 months. The app […]
onedrop
MannKind combines inhaled insulin with One Drop’s digital diabetes tech
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with […]
One Drop, MannKind ink partnership for connected, inhaled diabetes tech
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform. The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech. […]